

Edgar Filing: ARRAY BIOPHARMA INC - Form SC 13G/A

ARRAY BIOPHARMA INC
Form SC 13G/A
February 11, 2003

CUSIP No. 04269X10

13G

PAGE 1 OF 7 PAGES

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response . . . 11

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 2) *

Array BioPharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04269X10

(CUSIP Number)

December 31, 2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 04269X10

13G

PAGE 2 OF 7 PAGES

Schedule 13G

Edgar Filing: ARRAY BIOPHARMA INC - Form SC 13G/A

- Item 1(a). Name of Issuer: Array BioPharma, Inc. (the "Issuer").
- Item 1(b). Address of Issuer's Principal Executive Offices: 3200 Walnut Street, Boulder, CO 80301.
- Item 2(a). Names of Persons Filing: ARCH Venture Fund III, L.P. ("ARCH Venture Fund III"); ARCH Venture Partners, L.L.C. ("AVP LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity") and Steven Lazarus ("Lazarus"), Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
- Item 2(b). Address of Principal Business Office or, if None, Residence: 8725 W. Higgins Road, Suite 290, Chicago, IL 60631.
- Item 2(c). Citizenship: ARCH Venture Fund III is a limited partnership organized under the laws of the State of Delaware. AVP LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
- Item 2(d). Title of Class of Securities: Common Stock, \$.01 par value (the "Common Stock").
- Item 2(e). CUSIP Number: 04269X10
- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.
- Item 4. Ownership.

Each Reporting Person has ceased to own beneficially more than 5% of the outstanding Common Stock of the Issuer.

ALL OTHER ITEMS REPORTED ON THE SCHEDULE 13G DATED AS OF FEBRUARY 11, 2002 AND FILED ON BEHALF OF THE REPORTING PERSONS WITH RESPECT TO THE COMMON STOCK OF THE ISSUER REMAIN UNCHANGED.

----- CUSIP No. 04269X10 -----	13G	----- PAGE 3 OF 7 PAGES -----
--------------------------------------	-----	-------------------------------------

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2003

ARCH VENTURE FUND III, L.P.

By: ARCH Venture Partners, L.L.C.
its General Partner

By: *

Steven Lazarus

Edgar Filing: ARRAY BIOPHARMA INC - Form SC 13G/A

Managing Director

ARCH VENTURE PARTNERS, L.L.C.

By: *

Steven Lazarus
Managing Director

*

Steven Lazarus

*

Keith Crandell

*

Robert Nelsen

*

Clinton Bybee

* By: /s/ Mark McDonnell

Mark McDonnell as
Attorney-in-Fact

This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.

CUSIP No. 04269X10

13G

PAGE 4 OF 7 PAGES

Exhibit 1

AGREEMENT

Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Array BioPharma, Inc.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: February 10, 2003

ARCH VENTURE FUND III, L.P.

By: ARCH Venture Partners, L.L.C.
its General Partner

By: *

Steven Lazarus
Managing Director

ARCH VENTURE PARTNERS, L.L.C.

Edgar Filing: ARRAY BIOPHARMA INC - Form SC 13G/A

By: ARCH Venture Partners, L.P.
its General Partner

By: ARCH Venture Corporation
its General Partner

By: /s/ Steven Lazarus

Managing Director

ARCH II PARALLEL FUND, L.P.

By: ARCH Management Partners II, L.P.
its General Partner

By: ARCH Venture Partners, L.P.
its General Partner

By: ARCH Venture Corporation
its General Partner

By: *

Steven Lazarus
Managing Director

CUSIP NO. 04269X10

13G

PAGE 6 OF 7 PAGES

ARCH MANAGEMENT PARTNERS II, L.P.

By: ARCH Venture Partners, L.P.
its General Partner

By: ARCH Venture Corporation
its General Partner

By: /s/ Steven Lazarus

Managing Director

ARCH VENTURE PARTNERS, L.P.

By: ARCH Venture Corporation
its General Partner

By: /s/ Steven Lazarus

Managing Director

ARCH VENTURE CORPORATION

By: /s/ Steven Lazarus

Managing Director

ARCH VENTURE FUND III, L.P.

By: ARCH Venture Partners, L.L.C.
its General Partner

Edgar Filing: ARRAY BIOPHARMA INC - Form SC 13G/A

By: /s/ Steven Lazarus

Steven Lazarus
Managing Director

ARCH VENTURE PARTNERS, L.L.C.

By: /s/ Steven Lazarus

Steven Lazarus
Managing Director

/s/ Steven Lazarus

Steven Lazarus

/s/ Keith Crandell

Keith Crandell

CUSIP NO. 04269X10

13G

PAGE 7 OF 7 PAGES

/s/ Robert Nelsen

Robert Nelsen

/s/ Clinton Bybee

Clinton Bybee